HOOK2 Inhibitors
HOOK2 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the protein known as HOOK2. HOOK2, short for Hook microtubule-tethering protein 2, is a crucial component of the cellular machinery responsible for intracellular transport and organization. It plays an essential role in regulating the transport of cellular cargo along microtubules, which are structural components of the cell's cytoskeleton. This process is vital for various cellular functions, including the maintenance of cell shape, intracellular trafficking of organelles, and cell division.
The development of HOOK2 inhibitors has primarily focused on disrupting its interaction with other cellular proteins, such as dynein and kinesin motor proteins, which are responsible for the movement of cargo along microtubules. By inhibiting the function of HOOK2, these inhibitors can modulate intracellular transport processes. This class of compounds typically consists of small molecules designed to bind specifically to HOOK2 or interfere with its binding to other proteins, ultimately leading to a disruption in the proper transport of cellular cargo.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Inhibits the BCR-ABL tyrosine kinase, used in chronic myeloid leukemia (CML) and certain types of gastrointestinal stromal tumors (GISTs). | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Targets the epidermal growth factor receptor (EGFR) tyrosine kinase, used for the therapy of non-small cell lung cancer (NSCLC). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Inhibits multiple kinases, including RAF kinases and VEGFR, used in advanced renal cell carcinoma and hepatocellular carcinoma. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Targets the EGFR tyrosine kinase, used for the therapyof NSCLC and pancreatic cancer. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits BCR-ABL and Src family kinases, used for CML therapy and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Targets EGFR and HER2 kinases, used in the therapy of HER2-positive breast cancer. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Inhibits BRAF V600E kinase, used for the therapy of melanoma with this specific mutation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Inhibits Bruton's tyrosine kinase (BTK), used for the therapy of various B-cell malignancies, including chronic lymphocytic leukemia (CLL). | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Targets BCL-2 protein, used for the therapy of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Inhibits PARP enzymes, used as a targeted therapy for ovarian, breast, and prostate cancers with BRCA1/2 mutations. | ||||||